![]() ![]() As such, variable growth rate should be taken into account when considering active surveillance in young patients and when designing trials for evaluation of anti-cancer agents. Renal tumors tend to grow faster in young patients. The growth rate of “clinically significant” renal cancer appears to be higher than the rate reported in surveillance trials. Patient gender or Fuhrman’s grade did not correlate however. Tumor growth rate correlated inversely with patient’s age (p = 0.007). According to the proposed model, the average growth rate of “clinically significant” renal carcinomas was 2.13 cm/year (SD 1.45, range 0.2–6.5 cm/year). Mean time period from the normal imaging to diagnosis of renal cancer was 33.6 months (SD 18 months). Mean tumor diameter was 4.5 cm (SD 2.4 cm). Tumor growth rate was calculated by dividing tumor’s largest diameter by the time interval between the normal kidney imaging and diagnosis of renal cancer. All had a cross-sectional imaging studies performed 6–60 months prior to diagnosis of kidney cancer demonstrating no tumor. ![]() 46 patients (mean age 64 years SD 11 years) were treated for renal carcinoma. In the current report, we attempt to evaluate the growth rate of “clinically significant” renal carcinomas defined as tumors that were treated immediately upon diagnosis. In most of these studies however, only small tumors in elderly patients were followed. ![]() Surveillance studies of enhancing renal masses report on a mean tumor growth rate of about 0.3 cm/year. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |